CN101495111A - 在联合治疗中使用免疫调节化合物的方法和组合物 - Google Patents

在联合治疗中使用免疫调节化合物的方法和组合物 Download PDF

Info

Publication number
CN101495111A
CN101495111A CNA2007800277224A CN200780027722A CN101495111A CN 101495111 A CN101495111 A CN 101495111A CN A2007800277224 A CNA2007800277224 A CN A2007800277224A CN 200780027722 A CN200780027722 A CN 200780027722A CN 101495111 A CN101495111 A CN 101495111A
Authority
CN
China
Prior art keywords
amino
pharmaceutically acceptable
acceptable salt
effective dose
diketone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800277224A
Other languages
English (en)
Chinese (zh)
Inventor
多米尼克·维希里
凯乐·陈
劳拉·克拉尔
劳瑞·穆塔-德帕塞维尔
海伦·布拉迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CN101495111A publication Critical patent/CN101495111A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CNA2007800277224A 2006-05-26 2007-05-24 在联合治疗中使用免疫调节化合物的方法和组合物 Pending CN101495111A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80860206P 2006-05-26 2006-05-26
US60/808,602 2006-05-26

Publications (1)

Publication Number Publication Date
CN101495111A true CN101495111A (zh) 2009-07-29

Family

ID=38606531

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800277224A Pending CN101495111A (zh) 2006-05-26 2007-05-24 在联合治疗中使用免疫调节化合物的方法和组合物

Country Status (11)

Country Link
EP (1) EP2023912A2 (https=)
JP (1) JP2009538318A (https=)
KR (1) KR20090014393A (https=)
CN (1) CN101495111A (https=)
AU (1) AU2007267928A1 (https=)
CA (1) CA2652888A1 (https=)
IL (1) IL195412A0 (https=)
MX (1) MX2008014912A (https=)
RU (1) RU2426542C2 (https=)
WO (1) WO2007139939A2 (https=)
ZA (1) ZA200809956B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510983A (ja) * 2008-01-29 2011-04-07 セルジーン コーポレイション Ｃｄ５９のレベルを調節するための、免疫調節化合物を使用する方法
CA2868302A1 (en) * 2012-03-23 2013-09-26 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
KR20210021602A (ko) * 2013-08-22 2021-02-26 반다 파마슈티칼즈, 인코퍼레이티드. 다발성 골수종 치료
EP3616754A1 (en) 2013-08-22 2020-03-04 Vanda Pharmaceuticals Inc. Cancer treatment
CN112063586A (zh) * 2014-03-26 2020-12-11 布里格姆及妇女医院股份有限公司 用于人造血干/祖细胞的离体扩增的组合物和方法
WO2015175916A1 (en) * 2014-05-16 2015-11-19 Celgene Corporation Methods and compositions using 4-amino-2-(2,6 dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment of cancers
US20240360411A1 (en) * 2021-09-01 2024-10-31 Flagship Pioneering Innovations Vi, Llc Methods and compositions for inducing fetal hemoglobin, modulating erythroid cell lineages, and perturbing megakaryocyte lineages
EP4612128A4 (en) 2022-11-04 2025-09-10 Bristol Myers Squibb Co COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HEMOGLOBINOPATHIES

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
CA2752124A1 (en) * 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of head and neck cancer
BR0315609A (pt) * 2002-10-24 2005-08-23 Celgene Corp Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
KR20060109979A (ko) * 2003-12-02 2006-10-23 셀진 코포레이션 혈색소병증　및　빈혈의　치료　및　관리를　위한　방법및　조성물
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation

Also Published As

Publication number Publication date
ZA200809956B (en) 2010-07-28
AU2007267928A1 (en) 2007-12-06
CA2652888A1 (en) 2007-12-06
MX2008014912A (es) 2008-12-10
KR20090014393A (ko) 2009-02-10
IL195412A0 (en) 2009-08-03
EP2023912A2 (en) 2009-02-18
RU2426542C2 (ru) 2011-08-20
WO2007139939A3 (en) 2008-07-03
JP2009538318A (ja) 2009-11-05
WO2007139939A2 (en) 2007-12-06
RU2008151713A (ru) 2010-07-10

Similar Documents

Publication Publication Date Title
AU2004296765B2 (en) Methods and compositions for the treatment and management of hemoglobinopathy and anemia
US20080051431A1 (en) Methods and compositions using immunomodulatory compounds in combination therapy
JP4481828B2 (ja) 骨髄異形成症候群を治療および管理するための免疫調節化合物の使用方法およびそれを含む組成物
AU2005304420A1 (en) Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
JP2007534632A (ja) アスベスト関連疾患および障害の治療および管理のための免疫調節化合物の使用方法およびそれを含む組成物
ZA200608568B (en) Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
CN101495111A (zh) 在联合治疗中使用免疫调节化合物的方法和组合物
WO2012078492A1 (en) A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
US20080199422A1 (en) Method for the Treatment of Myelodysplastic Syndromes Using 1-Oxo-2-(2,6-Dioxopiperidin-3-Yl-)-4-Methylisoindoline
CA2621368A1 (en) Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
HK1133198A (en) Methods and compositions using immunomodulatory compounds in combination therapy
AU2014202561B2 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
HK1112912A (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
HK1100262B (en) Methods and compositions for the treatment and management of hemoglobinopathy and anemia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1133198

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090729

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1133198

Country of ref document: HK